SMTI Sanara MedTech Inc.
FY2024 10-K
Sanara MedTech Inc. (SMTI) filed its fiscal year 2024 10-K annual report with the SEC on Mar 25, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business model: Developer and marketer of surgical, chronic wound, and skincare technologies with value-based care services
- • New emphasis on Tissue Health Plus segment launching first pilot in Q2 2025 for value-based wound care targeting Medicare Advantage payers
Management Discussion & Analysis
- • Revenue and profit figures not disclosed in MD&A section
- • No segment performance details provided
Risk Factors
- • Regulatory risk: FDA 510(k) clearance required for products like BIASURGE and Chemo Mouthpiece, impacting go-to-market timing
- • Macroeconomic risk: Medicare Advantage payers targeted by Tissue Health Plus segment, exposed to changes in US healthcare reimbursement policies
Financial SummaryXBRL
Revenue
$87M
Net Income
-$10M
Gross Margin
90.6%
Operating Margin
-7.7%
Net Margin
-11.2%
ROE
-24.5%
Total Assets
$88M
EPS (Diluted)
$-1.14
Operating Cash Flow
-$23,784
Source: XBRL data from Sanara MedTech Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Sanara MedTech Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.